Insider Purchases: Inside the Buy

Tag: Oncology

Illustration of a biotechnology researcher and investor reviewing Kura Oncology charts beside a rising oncology treatment pipeline, highlighting KURA stock analysis, KOMZIFTI commercialization and biotech growth.

🧬 Kura Oncology (KURA) Stock Analysis: From Clinical Promise to Commercial Reality

Kura Oncology is evolving from a clinical-stage biotech into a commercial oncology company. With KOMZIFTI gaining traction, over $500 million in cash, strong institutional ownership and multiple Phase 3 catalysts ahead, is KURA becoming one of biotech's most compelling long-term opportunities?

Read entire article

Tags: AML, Biotech Innovation, Biotech Investing, Biotech Picks, biotech pipeline, biotech stocks, biotechnology investing, BiotechStocks, buy or sell KURA, cancer treatment, featured-insiders, FUNanc1al, FunStock Index, growth investing, healthcare stocks, hub-insiders, insider buying, InsiderBuying, KOMZIFTI, KURA, Kura Oncology, Kura Oncology stock analysis, KURA stock, KuraOncology, MeninInhibitor, Oncology, oncology stocks, precision medicine, risks buying KURA, ShortSqueeze, TroyWilson, why buy KURA, ziftomenib
Editorial illustration depicting a physician reviewing Pfizer's financial outlook alongside biotechnology imagery, DNA strands, oncology research, dividend metrics, insider buying indicators, and rising valuation charts.

💊 Pfizer (PFE): Why a Former Vanguard CEO Just Bought Nearly $1 Million of This 6.4% Dividend Stock

Pfizer has spent years under pressure following the collapse of pandemic-era revenues. Yet beneath the headlines, the company's non-COVID business is strengthening, oncology is expanding through Seagen, and two highly respected directors—including former Vanguard CEO and CIO Tim Buckley—recently invested nearly $2 million of their own money. We examine whether Wall Street is overlooking one of healthcare's most compelling value opportunities.

Read entire article

Tags: AlbertBourla, Biotech, buy or sell PFE, Deep Value, Dividend Investing, Dividend Stocks, FUNanc1al, GLP-1, Healthcare, Healthcare Stocks, HighDividend, Insider Buying, Insider Purchases, Long-Term Investing, MortimerBuckley, Oncology, PFE, Pfizer, Pharmaceuticals, Rare Diseases, risks buying PFE, Ronald Blaylock, Seagen, Tim Buckley, Vaccines, Value Investing, ValueInvesting, Vanguard, why buy PFE
A vibrant infographic showing a DNA double helix, syringes, a downward-sloping stock chart turning upward, and a confident CEO dropping a golden coin into the Moderna logo, labeled “$5M Insider Buy”

Moderna: Messenger RNA Medicines Powerhouse Sends A New Message — “Discount!”

Insiders dropped $6M on Moderna stock. With a massive mRNA pipeline and deep-pocketed backers, is this biotech beast ready to roar again?

Read entire article

Tags: Baillie Gifford, Biotech Stocks, Cash Burn, CEO insider buying, Checkpoint Immunotherapy, COVID, Cytomegalovirus, Director Insider Buying, Finance with Fun, Funanc1al Insider Series, Funanc1alInsiderSeries, Healthcare Innovation, insider buying, Insider Buys, Insider Purchases, InsiderActivity, InsiderBuying, InsiderPurchases, InsiderScoops, Investment Ideas, Moderna, MRNA, MRNA Stock, Norovirus, Oncology, Pharma, R&D, Rare diseases, RSV, Stock Market, Vaccine Stocks, Valuation Biotech, Wall Street